Search Our Website:
May 3 2018

​Barbara Binzak Blumenfeld, Shareholder in the FDA & Biotechnology practice group, moderated a panel on May 3 on "Regenerative Medicine and the Changing Regulatory Landscape" at the Food and Drug Law Institute's annual conference in Washington, DC.  The standing room only session, which included a Senior Policy Advisor at FDA among the panelists, addressed FDA's updated regulatory framework for stem cell and gene therapy products.  The session also discussed FDA's enforcement approach, and the impacts of regenerative medicine regulation on patients, the pharmaceutical and biotechnology industries, and insurers.